Dietary Supplement Use and Risk of Neoplastic Progression in Esophageal Adenocarcinoma: A Prospective Study
- 28 December 2007
- journal article
- research article
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 60 (1) , 39-48
Abstract
The incidence of esophageal adenocarcinoma (EA) and its precursor condition, Barrett's esophagus, has risen rapidly in the United States for reasons that are not fully understood. Therefore, we evaluated the association between use of supplemental vitamins and minerals and risk of neoplastic progression of Barrett's esophagus and EA. The Seattle Barrett's Esophagus Program is a prospective study based on 339 men and women with histologically confirmed Barrett's esophagus. Participants underwent baseline and periodic follow-up exams, which included endoscopy and self-administered questionnaires on diet, supplement use, and lifestyle characteristics. Use of multivitamins and 4 individual supplements was calculated using time-weighted averages of reported use over the observational period. Cox proportional-hazards models were used to calculate hazard ratios (HR) for each endpoint: EA, tetraploidy, and aneuploidy. During a mean follow-up of 5 yr, there were 37 cases of EA, 42 cases of tetraploidy, and 34 cases of aneuploidy. After controlling for multiple covariates including diet, nonsteroidal anti-inflammatory drug use, obesity, and smoking, participants who took 1 or more multivitamin pills/day had a significantly decreased risk of tetraploidy [HR = 0.19; 95% confidence interval (CI) = 0.08–0.47) and EA (HR = 0.38; 95% CI = 0.15–0.99] compared to those not taking multivitamins. Significant inverse associations were also observed between risk of EA and supplemental vitamin C (≥ 250 mg vs. none: HR = 0.25; 95% CI = 0.11–0.58) and vitamin E (≥ 180 mg vs. none: HR = 0.25; 95% CI = 0.10–0.60). In this cohort study, use of multivitamins and single antioxidant supplements was associated with a significantly reduced risk of EA and markers of neoplastic progression among individuals with Barrett's esophagus.Keywords
This publication has 66 references indexed in Scilit:
- NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal AdenocarcinomaPLOS Medicine, 2007
- Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagusCarcinogenesis, 2007
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC–EURGAST)International Journal of Cancer, 2006
- Serum concentrations of β-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult populationEuropean Journal of Clinical Nutrition, 2005
- Focus on Barrett's esophagus and esophageal adenocarcinomaCancer Cell, 2004
- Biomarkers of Esophageal Adenocarcinoma and Barrett’s EsophagusCancer Research, 2004
- Reflux, Barrett's oesophagus and adenocarcinoma: burning questionsNature Reviews Cancer, 2003
- Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, MinnesotaGut, 2001
- Obstruction of the superior vena cava after chemotherapyArchives of internal medicine (1960), 1985